Changes in Erythroblast Morphology as an Index of Response to Cyanocobalamin in Patients with Megaloblastic Anaemia

Dawson, Deborah; Lewis, Michael J.; Wadsworth, Louis D.

doi:10.1111/j.1365-2141.1975.tb00834.x

Cited by 3 publications

(1 citation statement)

References 14 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with PA and concurrent folate deficiency, combined vitamin B 12 and folate treatment was more effective than either alone. 48 However, other morphologic features and megaloblastic characteristics in the myeloid lineage were not reported. Another study evaluated the peripheral blood smears for neutrophil hypersegmentation in 23 patients with MA during vitamin B 12 and folate therapy.…”

Section: Partially Treated Megaloblastic Anemiamentioning

confidence: 99%

How I investigate acquired megaloblastic anemia

Torrez

Chabot‐Richards

Babu

et al. 2022

Int J Lab Hematology

View full text Add to dashboard Cite

In this review of megaloblastic anemia (MA), an overview of vitamin B 12 and folate body requirements, biochemical pathways, and laboratory testing strategies will be provided. However, the focus of this review is the classic and unique features of MA in blood and bone marrow. Acquired MA is a benign disorder for many, but can be detrimental for some. The clinical presentation can vary considerably, and the spectrum of symptoms and signs is diverse and quite broad. Prompt recognition and therapy are critical to prevent potential irreversible damage and clinical sequelae, especially in patients with vitamin B 12 deficiency. A delay in diagnosis of vitamin B 12 deficiency can result in significant neurologic sequelae that may not fully resolve with treatment, including in neonates and young infants. The blood and bone marrow features in MA can closely mimic thrombocytopenic purpura, myelodysplasia, and other myeloid neoplasms. Both pancytopenia and normal MCV at presentation are common in MA and raise unique challenges for the diagnostician. Partially treated MA is also a significant diagnostic "trap". MA is highly responsive to treatment, and patients tend to improve rapidly upon treatment initiation. However, the broad range of clinical and hematologic features makes the rapid, successful diagnosis of MA a unique challenge for the hematopathologist. Even in the era of state-of-the-art laboratory testing, a high suspicion is required.

show abstract

Section: Partially Treated Megaloblastic Anemiamentioning

confidence: 99%